Search

Your search keyword '"Davis, Brian J."' showing total 182 results

Search Constraints

Start Over You searched for: Author "Davis, Brian J." Remove constraint Author: "Davis, Brian J." Database Unpaywall Remove constraint Database: Unpaywall
182 results on '"Davis, Brian J."'

Search Results

1. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies

2. ACR-ARS Practice Parameter for the Performance of Proton Beam Therapy

3. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis

4. Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study

5. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer

6. Supplementary Table 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

7. Supplementary Methods from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

8. Data from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

9. Supplementary Figure 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

10. Supplementary Figure Legends from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

11. Supplementary Figure 2 from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

12. SupplementaryFigure 1 from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

13. Supplementary Figure 3 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

14. SupplementaryFigure 1 from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

15. Supplementary Figure Legends from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

16. Supplementary Table 2 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

17. Supplementary Figure 2 from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

18. Data from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

19. Supplementary Methods from Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

20. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis

21. Cost effectiveness of treatment strategies for high risk prostate cancer

22. A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient‐reported quality of life

23. The ABR 2021 Radiation Oncology Remote Examinations: Development, Administration, and Implications for the Future

24. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer

25. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

26. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

27. Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement

29. Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy

30. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

32. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer

33. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features

34. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients

36. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer

37. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

38. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer

40. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate

41. Comparing bowel and urinary domains of patient‐reported quality of life at the end of and 3 months post radiotherapy between intensity‐modulated radiotherapy and proton beam therapy for clinically localized prostate cancer

42. Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center

44. c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner

47. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

48. 11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities

Catalog

Books, media, physical & digital resources